COVID-19 pneumonia patients with 25(OH)D levels lower than 12 ng/ml are at increased risk of death
et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.01.044
, COVID-19 pneumonia patients with 25(OH)D levels lower than 12 ng/ml are at increased risk of death, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.01.044
Retrospective 357 COVID-19 pneumonia patients in Slovakia, showing higher mortality with vitamin D deficiency (<12ng/mL). All patients received vitamin D supplementation in hospital. In multivariable linear regression, vitamin D levels were independently associated with mortality (p=0.0398).This is the 111th of 175 COVID-19 sufficiency studies for vitamin D, which collectively show higher levels reduce risk with p<0.0000000001 (1 in 18 vigintillion).
|
risk of death, 19.0% lower, RR 0.81, p = 0.05, high D levels (≥12ng/mL) 127 of 283 (44.9%), low D levels (<12ng/mL) 41 of 74 (55.4%), NNT 9.5.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Juraj et al., 22 Jan 2022, retrospective, Slovakia, peer-reviewed, 13 authors, study period 1 November, 2020 - 30 April, 2021.
Contact:
smaha1@uniba.sk.
Patients with COVID-19 pneumonia with 25(OH)D levels lower than 12 ng/ml are at increased risk of death
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.01.044
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
assessment at admission could be relevant for the risk stratification and planning for treatment strategy in patients with COVID-19.
Conflict of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Ethical Approval Statement The study was conducted in accordance with the Declaration of Helsinki and was approved by The Ethics Committee of the University Hospital Bratislava. An informed and written consent was obtained either from the participants or a first degree relative.
References
Amrein, Scherkl, Hoffmann, Neuwersch-Sommeregger, Köstenberger et al., Vitamin D deficiency 2.0: an update on the current status worldwide, Eur J Clin Nutr, doi:10.1038/s41430-020-0558-y
Baktash, Hosack, Patel, Shah, Kandiah et al., Vitamin D status and outcomes for hospitalized older patients with COVID-19, Postgrad Med J, doi:10.1136/postgradmedj-2020-138712
Beyerstedt, Casaro, Rangel, COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection, Eur J Clin Microbiol Infect Dis, doi:10.1007/s10096-020-04138-6
Bishop, Ismailova, Dimeloe, Hewison, White, Vitamin D and immune regulation: antibacterial, antiviral, anti-inflammatory, JBMR Plus, doi:10.1002/jbm4.10405
Cashman, Vitamin D Deficiency: Defining, Prevalence, Causes, and Strategies of Addressing, Calcif Tissue Int, doi:10.1007/s00223-019-00559-4
Chen, Mei, Xie, Yuan, Ma et al., Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis GRADE assessment of cohort studies and RCTs, Nutr J, doi:10.1186/s12937-021-00744-y
Getachew, Tizabi, Vitamin D and COVID-19: Role of ACE2, age, gender, and ethnicity, J Med Virol, doi:10.1002/jmv.27075
Giustina, Adler, Binkley, Bollerslev, Bouillon et al., Consensus statement from 2 nd International Conference on Controversies in Vitamin D, Rev Endocr Metab Disord, doi:10.1007/s11154-019-09532-w
Grant, Lahore, Mcdonnell, Baggerly, French et al., Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths, Nutrients, doi:10.3390/nu12040988
Hansdottir, Monick, Vitamin D effects on lung immunity and respiratory diseases, Vitam Horm, doi:10.1016/B978-0-12-386960-9.00009-5
Hetta, Muhammad, El-Masry, Taha, Ahmed et al., The interplay between vitamin D and COVID-19: protective or bystander?, Eur Rev Med Pharmacol Sci, doi:10.26355/eurrev_202102_25119
Hewison, An update on vitamin D and human immunity, Clin Endocrinol (Oxf), doi:10.1111/j.1365-2265.2011.04261
Hussain, Jabeen, Raza, Shabbir, Baig et al., Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein, J Med Virol, doi:10.1002/jmv.25832
Lips, Cashman, Lamberg-Allardt, Bischoff-Ferrari, Obermayer-Pietsch et al., Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society, Eur J Endocrinol, doi:10.1530/EJE-18-0736
Martineau, Forouhi, Vitamin D for COVID-19: a case to answer?, Lancet Diabetes Endocrinol, doi:10.1016/S2213-8587(20)30268-0
Martineau, Jolliffe, Hooper, Greenberg, Aloia et al., Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data, BMJ, doi:10.1136/bmj.i6583
Mascolo, Scavone, Rafaniello, Angelis, Urbanek et al., The Role of Renin-Angiotensin-Aldosterone System in the Heart and Lung: Focus on COVID-19, Front Pharmacol, doi:10.3389/fphar.2021.667254
Merad, Martin, Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages, Nat Rev Immunol, doi:10.1038/s41577-020-0331-4
Murai, Fernandes, Sales, Pinto, Goessler et al., Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.